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Summary 
Atrial natriuretic factor, the first well defined natriuretic hormone is 
synthesized in the human heart as151 aminoacid (AA) preprohormone and 
stored, as 126 AA prohormone in atrial ~anules. Ulbon apEropriate 
stimulation, the prohormone is cleaved into a 98 AA N-terminal tragment 
and a 28 AA C-terminal fragment, he biological active ANF(99-126), both 
circulating in plasma. Circulating ANF(99-126) is cleared by various organs, 
such as lung, liver and intestine, kidney and upper and lower limbs. Reported 
arterial-venous extraction ratios vary greatly, but are not much different 
between organs, the average extraction ratio being about 35 %. Due to 
marked ifferences of organ blood flow, the contributaon ot various organs to 
total body ANF clearance differs considerably. Major mechanisms for ANF 
clearance are uptake by clearance receptors and degradation by an 
endoprotease (E-C 3.4.24.11.). Clearance receptors, disrtinct from the 
receptors mediating the biological actions ofANF, have been demonstrateO 
in vg_rious organs. Characterization f the ANF degrad~g enzyme activity has 
been performed in kidney tissue. Whether and how pathophysiological states 
affect ANF clearance is still poorly understood. Inhibition of clearance by 
ANF analogues binding to clearance receptors and by inlaibitors of degrading 
peptidase can increase the biological action of circulating ANF. This may 
prove to be a therapeutic approach in diseases with smooth muscle 
contraction orvolume overload. 
Atrial natriuretic factor is the first well-defined natriuretic hormone. The best characterized 
pharmacological nd partly physiological actions of ANF are natriuresis, diuresis and 
smooth muscle relaxation (for review see ref. 1-12). Recently, evidence has been provided 
that ANF might be involved in various other biological actions apart from its role in volume 
homeostasis such as immune or reproductive functions (13-17). ANF is synthesized in the 
human heart as a 151 amino acid pre-prohormone and stored as a 126 amino acid 
prohormone. Upon appropriate stimulation, such as atrial stretch, the prohormone is
cleaved into an N-terminal and C-terminal fragment. The latter has been identified as the 
circulating bioactive ANF(99-126) (18,19). A body of investigations has concentrated onthe 
mechanisms of ANF release and on its biologicalactions (for review 1-14). So far, there is 
much less information on the processing of ANF prohormone as well as on the clearance of 
bioactive ANF. However, these seem to be topms of considerable interest, since plasma 
levels and biological activity of ANF are significantly influenced by these processes. This 
review article wiI1 concentrate on the mechanisms of degradation and clearance of bioactive 
ANF, including pathophysiological aspects and possible therapeutic implications. The still 
poorly understood metabolism ofANF in the central nervous ystem will not be addressed 
in this article. 
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Plasma levels of bioactive ANF are determined by both, release and clearance. While there 
is a rich body of information about ANF release, the number of studies on the clearance of 
tl~i. "s peptide is rather limited (20-36). The ability of various organs to clear ANT from the 
circulation can be describe.d by the extraction ratio or by the organ clearance. The 
extraction ratio is calculateO as arterial minus venous blood concentration over arterial 
blood con~ntration (%). Multiplication of the extraction ratio with the organ plasma flow 
results in the organ clearance Oiter/min). Several aspects and possible pitfalls have to be 
taken into consideration, regarding studies on ANF metabolism. Since the studies 
necessarily apply venous, and partly even arterial catheterization, for ethical reasons many 
investigattous have been done in patients with hypertension or congestive laeart failure 
rather than in healthy subjects. Some of the studies did not determine organ plasma flow, 
thus restricting their results to extraction ratios. Extraction ratios as well as organ clearance 
have been determined both under basal conditions and following intravenous ANF 
8dmlnlstration. For clearance determinations of pharmacologically active ANT doses, 
specific attention should be paid to the rate of infusion in order to achieve steady state 
conditions. Problems may arise by inappropriate intervals of plasma sa .xn. pling. Furthermore, 
administration of ANF may decrease blood pressure (29), affect carcliac output and organ 
blood flow and increase giomerular filtration rate; this might result in under- or 
overestimation f ANF clearance as compared to physiological conditions. Furthermore, 
some studies are based on the assumption, that there is no pulmonary extraction of ANF. 
However, there is now evidence obtained by pulmonary wedge or pulmonary venous 
sampling (20,21), that the lung is an important site for ANF extraction. 
With these reservations in mind, it seems, that there is no major organ specificity for ANF 
extraction. Lung, liver, kidney, intestine and lower limb show similar extraction ratios within 
the respective studies. Values reported, however, differ considerably between various 
studies (Table 1)(20-24,26,27,29,31--34,36). Extraction ratios were reported to be 0% - 33% 
for lung, 22% - 75% for liver and intestine, 23% - 67% for kidney and 15% - 61% for the 
lower lfmb. Taken together, it seems, that there is a general arterio-venous organ extraction 
ratio for ANF of about 35%. Since there are marked differences of.organ blood flow, 
obviously total ANF clearance differs considerably between various organs. Few 
investigations have determined organ blood flow together with ANF extraction under 
physiological or steady-state conditions (20,22,24,29). About 50% of the total body 
clearance of ANF seems to be furnished by the lung (20). The renal (around 15%) 
(20,22,24) and splanchnic-hepatic (about 20%) (20,22,29) vascular beds also contribute 
significantly to ANF clearance. Several mechanisms could account for the above mentioned 
organ clearance of ANF: receptor-me0iatecl uptake, enzymatic degradation or organ- 
s celtic, excretion. (urine,. bile . However, there are onl%. few reports, of. concentrations of.
~a~ in bile (20) or urine (30,~5). Therefore, organ specific excretion will not be covered m 
this article. 
Enzymatic dem'adation 
Since the kidney is a major target organ for ANF, interest has focussed on this organ not 
only as a site for receptor mediated clearance of this peptide, but also as a tissue which may 
be able to enzymaticaqly degrade circulating ANF(99-12ti). Peptidase degradation of ANF fs 
considered to play an important, role among possible clearance mechanisms. . . (37,38). The
brush border of the renal proximal tubule is known to be very nch m peptldases. These 
enzTmes are membrane bound and their active sites face the lumen of  the tubule (39). 
Incubating ANF(99-126) with these kidney microvilli results in a major degradation product 
cleaved between cysteine and phenylalanine (C'ys 105-Phe 106) (37,38,40-42). Since the 
intact ring structure of ANF(99-126) is essential for its biological activity (43,44), ANF is 
effectively inactivated by this cleavage process. 
The properties of the ANF degrading activity have been investigated by several groups. The 
responsl"ole substance is a glycoproteln (37,40,42) with a molecular wexght of approxtmately 
94 kD, sensitive to metalloendoprotease inhibitors uch as phosphoramidon a d thiorphan. 
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seems to be the endoprotease EC 3.4,24.11 (37,40,42). EC 3.4.24.11 has been reported also 
to possess enkephaliri degrading activity. ~45). However, there may be various forms of EC 
3.4.24.11, differing in cleavage site speL-ificity and tissue distributmn (40,46-50). Thus, one 
may speculate that the kidney p9ssesses a specific type of end oprotease EC 3.4.24.11. Apart 
from fhe major cleavage site within the loop structure, secondary attack by aminopeptidases 
has been hyp.othesized (37). These e .n~cmes are not initially responsible for degradation, 
because spe~fic inhibitors like captopril o_r amastatin had no sighificant ettect (37). After 
the major cleavage process at the Cys-Phe bond of the ring structure, more complex 
degradation processes seem to follow, producing smaller ANF fragments (41). The major 
sites of renaI ANF degradation by the endopepfidase em to be the proximal tubule and 
the glomerulus (51). Prompted by these observations, ettOrts have been made to develop 
ANF analogues, which are resistent to this enzyme, as well ..as specific enzyme inhibitors, 
which could be therapeutically employed. R cent reports indicate ANF degrading activity 
by the vasculature (52) and the adrenal capsule (46).-No information is available about he 
enzymatic degradation activity of other organs reported to contribute to ANF clearance. 
Clearance receutors 
Specific binding sites for atrial natriuretic factor have been identified on various cells, such 
as endothelial cells, vascular smooth muscle cells, inner medullary collecting duct cells and 
in various organs, such as lung, kidney, a~enal gland) liver and intestine (53-55). Several 
observations demonstrate hat mere are at least two different types of ANFreceptors with 
different molecular size and different biological properties (56-61). The development of 
truncated ANF analogues which selectively hind to one receptor typesuch as des[(18-22)]- 
rANF(4-23~NH 2 (62,63), recently has allowed for better _quantitatwe aiscrimination ofboth 
receptors. The current concept of both receptors i as follows: the 130 kD receptor exhibits 
a higher affinity for circulating biologically active ANF, is coupled to guanylate cyclase and 
mediates the biological effects. Thus It has been called B- (Bidloglcal)- or Rl-receptor. The 
other receptor type shows a molecular weight of 65 kD, exhibits a lower affinity to 
biologically active ANF and binds truncated ANF analogues; it has thus been called C- 
(Clearance)- or R2-receptor (64-67). C-receptors might mediate suppression of adenylate 
cyclase activity by ANF (68,69). Interestingly, it has been shown that the C-receptor may 
regulate the biologic activity of endogenously released ANF (67), and there is evidence, that 
this receptor type mdeed has a clearance function (64). 
In anesthetized rats, administration of an ANF analogue selectively binding to C-receptors, 
induced marked dose-dependent i creases of ANF(99-126) plasma concentration, and 
decreases of its volume of distribution and metabolic learance rate. Furthermore, there is 
evidence, that a major part of ANF metabolism is due to an internalization following the 
binding of circulating A.~F to the C-receptor and subsequent intralysomal hydrolysis (64). 
The regulation of the C-receptor is poorly understood. There is evidence, that maneuvres 
decreasing intravascular volume decrease ANF plasma levels and in turn increase total 
ANF receptor density (70-72). Surprisingly, this increase of ANF receptor density, is coupled 
to a reduced biological response to ANF. The observation, tlaat C-receptors but not B- 
receptors are augmented following dehydration (73) could explain this seeming 
contradiction and indicates that regulation of C-receptor density might be involved in 
volume homeostasis. There are few data on the quantitative r lationship between B- and C- 
receptors in various tissues. In the kidney, in particular on glomeruli, the majority of ANF 
receptors eems to be of the clearance type (73,74). The same has been observed on 
cultured bovine aorta endothelial cells (56), on adrenal zona glomerulosa cells (74) and on 
lung membranes (61). These recent observations are compatible with the concept of a 
functional importance of the C-receptors, which are distinctly different trom the B- 
receptors, in the clearance of ANF - a rather unique mechanism in the metabolism of 
peptldes. 
Pathoohvsiolo~v 
Elevated plasma concentrations of ANF have been found in various pathophysiological 
states, such as congestive heart failure, renal failure and in some patients with liver disease 
(e.g. 75-78). An increased release of ANF h~ been suggested in these diseases (36,79-82). 
However, elevated plasma concentrations might also be caused by decreased clearance. To 
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date, little is known about clearance in pathophysiological states. Recently, it has been 
reported, that the fractional extraction of various organs is unchanged in patients with liver 
cirrhosis (27). In an experimental model it has been shown that the renal clearance of ANF 
varies considerably, depending upon glomerular filtration rate (24); thus, augmented ANF 
plasma concentrations m renal diseases might be partly due to reduced ANF elimination. 
Tile proportion of B- and. C-receptors for ANF in aorta, adrenal and kidney seems 
unchanged in experimental congestive laeart failure (74). In an experimental model of 
cirrhoms, C-receptor density on glomeruli was increased, whereas B-receptors tended to be 
decreased (83); however, these animals were not investigated for ANF clearance. Clearly, 
there is a need for further investigations on whether and how metabolic learance and 
degradation ofANF is affected by pathophysiological states. 
Theraueuti¢ implications 
Beneficial effects of ANF application have been reported in congestive heart failure, 
hypertension, renal failure, clironic obstructive lung disease and liver disease (84-91). 
Augmented circulating levels of ANF may be achieved by exogenous administration of 
ANF. Due to the peptide character of the substance, ANF can be administered only 
intravenously. The rapid metabolic learance (92-94) makes repeated bolus injections or 
continuous infusions necessary. Alternatively, circulating ANFconcentrations might be 
elevated by blocking its clearance. This might be achieved by administering truncated 
analogues, binding to clearance receptors only and thus au~.enting the concentration ot
ANF reaching the B-receptors (64,67,95). Furthermore, inhlbitors of the ANF degrading 
peptidase maght show the same results. Indeed, several investigations employin~ 
endopeptidase EC 3.4.24.11 inhibitors (95-105), showed that he circulating ANF 
immunoreactivity was elevated and this was accompanied by an ugmented biological 
activity, such as increased urinary volume and sodium excretion. Interestingly, these 
chemicals eem to be especially useful in pathophysiological conditions. They ti~/ve been 
shown to enhance the biological activities (natriuretic anddepressor responses) of ANF in 
experimental models of hypertension (97,103-105) and volume expansion (101). Further 
investigations will evaluate tlae potential of this rather elegant therapeutic approach. 
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